SCHEMBL697591

SCHEMBL697591

O=C(O)C(Cc1ccccc1)NS(=O)(=O)c1ccccc1

nearest known ligand 0.85

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 11/20 0.85
MMP9 P14780 10/20 0.85
ADAMTS4 O75173 1/20 0.85
ADAMTS5 Q9UNA0 1/20 0.74
ALDH1A1 P00352 1/20 0.74
MAPT P10636 1/20 0.74
MMP1 P03956 1/20 0.74
MMP3 P08254 1/20 0.74
MMP7 P09237 1/20 0.74
MMP13 P45452 1/20 0.74
POLB P06746 1/20 0.70
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
L3MBTL1 Q9Y468 2/20 0.63
TDP1 Q9NUW8 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4188026 1.00 MMP2 (0.85) MMP2MMP9ADAMTS4ADAMTS5ALDH1A1
SCHEMBL697592 1.00 MMP2 (0.85) MMP2MMP9ADAMTS4ADAMTS5ALDH1A1
SCHEMBL6545297 0.92 MMP2 (1.00) MMP2MMP9ADAMTS4ADAMTS5ALDH1A1
SCHEMBL1920507 0.92 MMP2 (1.00) MMP2MMP9ADAMTS4ADAMTS5ALDH1A1
SCHEMBL32691761 0.92 MMP2 (1.00) MMP2MMP9ADAMTS4ADAMTS5ALDH1A1
SCHEMBL8912956 0.91 L3MBTL1 (0.78) MMP2MMP9ADAMTS4ADAMTS5ALDH1A1
SCHEMBL3009406 0.90 MMP2 (0.92) MMP2MMP9ADAMTS4ADAMTS5ALDH1A1
SCHEMBL14218255 0.90 MMP2 (0.79) MMP2MMP9ADAMTS4ADAMTS5ALDH1A1
SCHEMBL8063645 0.90 TDP1 (0.78) MMP2MMP9ADAMTS4ADAMTS5ALDH1A1
SCHEMBL697477 0.90 MMP2 (0.79) MMP2MMP9ADAMTS4ADAMTS5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1457487-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES Toray Fine Chemicals Co., Ltd. (JP) 2004-09-15 EP claimed
US-20040171836-A1 Method for producing optical-active cis-piperidine derivatives TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) 2004-09-02 US claimed
US-20040062773-A1 Compositions for the delivery of antigens EMISPHERE TECHNOLOGIES INC. 2004-04-01 US claimed
EP-0784469-B1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECH INC (US) 2004-03-24 EP claimed
US-6610329-B2 Using acylated amino acid as carrier EMISPHERE TECHNOLOGIES INC. 2003-08-26 US claimed
US-20020001591-A1 Compositions for the delivery of antigens EMISPHERE TECHNOLOGIES, INC. 2002-01-03 US claimed
US-5958457-A MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS EMISPHERE TECHNOLOGIES, INC. (US) 1999-09-28 US claimed
EP-0784469-A4 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECH INC (US) 1999-03-24 EP claimed
EP-0784469-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS Emisphere Technologies, Inc. (US) 1997-07-23 EP claimed
WO-1996012474-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECHNOLOGIES, INC. (US) 1996-05-02 WO claimed
CN-105102430-A Process for the preparation of enantiomerically enriched 3-aminopiperidine REUTER CHEMISCHE APPBAU KG 2015-11-25 CN disclosed
EP-2423211-B1 PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF KANEKA CORP (JP) 2014-04-16 EP disclosed
EP-2423211-A1 PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF Kaneka Corporation (JP) 2012-02-29 EP disclosed
EP-1457487-A4 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES TORAY FINECHEMICALS CO LTD (JP) 2005-06-22 EP disclosed
EP-1457487-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES Toray Fine Chemicals Co., Ltd. (JP) 2004-09-15 EP disclosed
WO-2003053929-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES TORAY FINE CHEMICALS CO., LTD. (JP) 2003-07-03 WO disclosed
WO-2002085311-A2 HCG FORMULATION ACEVEDO HERNAN F (US) 2002-10-31 WO disclosed
US-6271247-B1 BINDING TO NEUROPEPTIDE RECEPTORS ADIR ET COMPAGNIE (FR) 2001-08-07 US disclosed
US-6172108-B1 NEUROPEPTIDE Y RECEPTOR LIGANDS; TREATING PSYCHOLOGICAL, EATING, SLEEP, AND SEXUAL DISORDERS; HYPOTENSIVE, ANXIOLYTIC, ANTIDEPRESSANT, AND ANTIDIABETIC AGENTS ADIR ET COMPAGNIE (FR) 2001-01-09 US disclosed
CN-1260345-A Hydrazide compound, its preparing method and medicine compositions thereof ADIR ET COMPANGIE (FR) 2000-07-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171836-A1 Method for producing optical-active cis-piperidine derivatives TYR, DDC, TARBP1 MMP2 1206/4885MMP9 1373/4885ADAMTS4 2548/4885
US-20020001591-A1 Compositions for the delivery of antigens CD47, CD74, LY96 MMP2 2444/4885MMP9 2979/4885ADAMTS4 3212/4885
US-20040062773-A1 Compositions for the delivery of antigens CD47, CD74, LY96 MMP2 2444/4885MMP9 2979/4885ADAMTS4 3212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.